PanGen Biotech Inc (222110) — Financial Flexibility Index
PanGen Biotech Inc (222110) has a Financial Flexibility Index of -1.27x as of September 2025. Free cash flow of ₩-3.47 Billion (operating CF ₩-3.66 Billion minus capex ₩196.18 Million) represents -1% of total liabilities (₩2.74 Billion). Check strategic asset allocation of PanGen Biotech Inc to assess the company's strategic physical and investment asset allocation.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
PanGen Biotech Inc Financial Flexibility Index (2014–2024)
Historical Financial Flexibility Index trend for PanGen Biotech Inc across 11 annual periods. See working capital to net assets of PanGen Biotech Inc to evaluate short-term liquidity relative to the company's equity base.
Annual Financial Flexibility Index for PanGen Biotech Inc (2014–2024)
Year-by-year free cash flow to debt coverage for PanGen Biotech Inc. For the full company profile including market capitalisation, see PanGen Biotech Inc stock valuation.
| Year | Flexibility Index | Free Cash Flow (KRW) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2024 | 0.60x | ₩3.36 Billion | ₩2.99 Billion | ₩5.64 Billion | ▲ +264.4% |
| 2023 | -0.36x | ₩-2.97 Billion | ₩-3.45 Billion | ₩8.18 Billion | ▲ +54.8% |
| 2022 | -0.80x | ₩-2.77 Billion | ₩-3.50 Billion | ₩3.45 Billion | ▼ -838.2% |
| 2021 | -0.09x | ₩-1.90 Billion | ₩-3.32 Billion | ₩22.18 Billion | ▲ +51.8% |
| 2020 | -0.18x | ₩-3.93 Billion | ₩-4.68 Billion | ₩22.10 Billion | ▼ -29.1% |
| 2019 | -0.14x | ₩-2.84 Billion | ₩-3.66 Billion | ₩20.66 Billion | ▲ +43.6% |
| 2018 | -0.24x | ₩-4.55 Billion | ₩-5.61 Billion | ₩18.67 Billion | ▼ -172.6% |
| 2017 | 0.34x | ₩1.44 Billion | ₩-657.84 Million | ₩4.28 Billion | ▲ +179.8% |
| 2016 | -0.42x | ₩-880.81 Million | ₩-4.35 Billion | ₩2.09 Billion | ▼ -15542.4% |
| 2015 | 0.00x | ₩-25.14 Million | ₩-1.61 Billion | ₩9.34 Billion | ▲ +97.9% |
| 2014 | -0.13x | ₩-792.03 Million | ₩-1.34 Billion | ₩6.18 Billion | — |